glp 1 agonist crohn's disease GLP-1 with Disease: Safety, Risks and Clinical Guidance – Bolt Pharmacy GLP-1 Use in Crohn's Disease:
Description
It could thus be assumed that in a state of high cardiovascular risk, the body tries to limit disease progression by increasing the secretion of the protective agent GLP-1
2024;36(6):1302-19.e12
However, the consistency of emerging data in both men and women raises the possibility that these medications may ultimately prove to have direct reproductive effects as well
These figures represent the largest weight reductions reported for any incretin-based compound at Phase 2 at the time of publication
Sols from Novo Nordisk A/S for performing a medical accuracy review
